WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient

European Journal of Haematology
Yusuke OjiHaruo Sugiyama

Abstract

How to treat CML patients who are resistant to inhibitors of BCR-ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib-treated CML in which intradermally administered WT1 peptide vaccine elicited WT1-specific immune responses and the resultant reduction in the persistent residual disease in co-administration of Imatinib. BCR-ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR-ABL mRNA levels was associated with the increase in frequency of WT1-specific cytotoxic T lymphocytes, notably effector-memory type of that, in the patient's peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure-oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib.

References

Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Sep 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yoshihiro OkaHaruo Sugiyama

❮ Previous
Next ❯

Citations

Dec 18, 2012·Cancer Cell International·Yangqiu LiChristian A Schmidt
Feb 12, 2013·Cancer Cell International·Chen Lin, Yangqiu Li
Aug 2, 2013·Haematologica·Angelo M CarellaJohn M Goldman
Nov 20, 2012·Journal of Cancer Research and Clinical Oncology·Takashi MiyatakeTadashi Kimura
Sep 18, 2015·Human Vaccines & Immunotherapeutics·Eva van DoornEelko Hak
May 14, 2016·International Journal of Cancer. Journal International Du Cancer·Yusuke OjiHaruo Sugiyama
Feb 20, 2018·Molecular Cancer·Michele MassiminoPaolo Vigneri
Jun 23, 2011·Expert Review of Vaccines·R Casalegno-GarduñoM Schmitt
Sep 8, 2011·Current Opinion in Hematology·Betul Oran, Marcos de Lima
Feb 17, 2011·Expert Review of Hematology·Gheath Alatrash, Jeffrey J Molldrem
Jun 13, 2017·The Journal of Veterinary Medical Science·Osamu SakaiTakuya Mizuno
Jan 10, 2019·Cancer Cell International·Yikai Zhang, Yangqiu Li
Mar 9, 2021·World Journal of Clinical Oncology·Mariana Miranda SampaioFabrício Freire de Melo
Jul 18, 2021·Cancer Immunology, Immunotherapy : CII·Hiroko NakajimaHaruo Sugiyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.